Gateway to Indonesia's Health Security

Delivering sovereign, scalable, and trusted

As a gateway to Indonesia's health security, the organization plays a strategic role in ensuring reliable and sustainable access to essential vaccines. By strengthening local production, expanding scalable manufacturing capacity, and collaborating with global innovators, it helps reduce dependence on imports and supports the continuity of national immunization programs, while contributing to long-term resilience in public health.

Biotis exists to strengthen health security by expanding access to high-quality vaccines and biologics.
We believe that every country deserves reliable access to essential vaccines and biologics, and every community deserves protection from preventable diseases.

Strategic Foundation

Core Strategic Pillars

Four key areas driving our mission to strengthen health security

Strengthening Local Production

Building sustainable vaccine production capacity in Indonesia

Expanding Access

Supporting national immunization and improving availability of essential vaccines and biologics

Global Partnership

Collaboration with international companies for technology transfer and innovation

Research & Innovation

Advancing R&D and quality assurance for safe, effective biologics

Our Contribution For

Building Protection

Protection does not happen by chance. It is built through science, manufacturing, and long-term commitment.

Behind every vaccine is a complex system of research, production, quality control, and distribution. Reliable protection depends on reliable manufacturing and the ability to deliver vaccines consistently, safely, and at scale.

Strengthening these capabilities is essential to ensuring that protection is available when it is needed most.

Building Protection

End-to-EndBiopharmaceutical Capabilites

Biotis operates a complete value chain, from upstream to finished product release.

Upstream Process

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu

Downstream Process

Drug Substance

Formulation

Filling

Visual Inspection

QC Testing

QA Release

Product Release

Featured Solution

We are committed to supporting national healthcare independence through the development of advanced vaccines and biological products designed to provide long-term protection for all communities

INAVAC

Lorem ipsum dolor sit amet consectetur adipisicing elit. Dicta officiis voluptate qui obcaecati voluptates, fuga iusto laborum hic esse inventore provident amet quis praesentium consequuntur ratione eius quas! Cupiditate, vel?

ComBE Five

Pulmeera

INAVAC

ComBE Five

Pulmeera

Built in Crisis, Proven in the Field

Our rapid mobilization during global health emergencies has solidified our role as a critical infrastructure partner. From 2020 to today, our milestones reflect unwavering growth.

2020

+Company incorporated
+Research collaboration with Airlangga University to develop COVID-19 vaccine
+Participated in the 'Vaksin Merah Putih' initiative

2021

+Initiated GMP Certification process
+Non-clinical trials for the COVID-19 vaccine
+Obtained a complete GMP Certification to produce vaccine
+Received Halal Certificate for INAVAC
+Received EUA (Emergency Use Authorization) for INAVAC from Indonesian FDA

2022

+Clinical trials for the COVID-19 vaccine
+Launched INAVAC as the first and only human vaccine developed and produced in Indonesia
+The Ministry of Health of The Republic of Indonesia started to purchase INAVAC from the Company
+Received a permanent marketing license (NIE) for INAVAC from BPOM (Indonesian FDA)
+Transfer technology agreement with Beijing Minhai Biotechnology Co., Ltd. (Minhai) (on April 2023)

2023

+Signed a partnership and technology transfer agreement with Biological E-India
+Received marketing license for DPT-HB-Hib (Penta Valent) vaccine from BPOM
+Signed a purchase contract for the Penta Valent Vaccine with the Ministry of Health of The Republic of Indonesia
+Signed a MOU with ALPS Global, a Malaysian-based healthcare company, that specializes in stem cell therapy

2024

+Signed a partnership and technology transfer agreement with LG Chem of South Korea
+The Ministry of Health of The Republic of Indonesia started to purchase PULMEERA from Biotis

2025

+Received a permanent marketing license (NIE) for PULMEERA from BPOM
+Received a HALAL certificate for PULMEERA from Halal Product Assurance Body

Biotis Ecosystem

Biotis works closely with universities, technology partners, global biopharmaceutical companies, and government institutions to strengthen local capabilities and expand access to essential vaccines. These collaborations play a vital role in supporting innovation, ensuring quality, and building a resilient health system.

News & Updates

Latest News

Stay updated with our latest developments, partnerships, and milestones

View All News

Biotis Receives WHO Prequalification for Pentavalent Vaccine

Regulatory

Feb 15, 20265 min read

Biotis Receives WHO Prequalification for Pentavalent Vaccine

This milestone marks a significant achievement in our mission to provide accessible, high-quality vaccines to communities worldwide. The WHO prequalification enables broader distribution across developing nations.

Read Article

Partnership

Feb 10, 20263 min read

Strategic Partnership with Global Health Initiative Announced

Biotis partners with leading global health organizations to expand vaccine access in Southeast Asia.

New Manufacturing Facility to Boost Production Capacity

Expansion

Feb 5, 20264 min read

New Manufacturing Facility to Boost Production Capacity

State-of-the-art facility equipped with advanced biotechnology infrastructure will significantly enhance our ability to meet growing regional demand.

Biotis Launches Pediatric Vaccine Education Campaign

CSR

Jan 28, 20263 min read

Biotis Launches Pediatric Vaccine Education Campaign

Comprehensive initiative aims to raise awareness about the importance of childhood immunization.

Research Breakthrough in mRNA Technology

R&D

Jan 20, 20266 min read

Research Breakthrough in mRNA Technology

Our R&D team achieves significant progress in developing next-generation vaccine platforms.

View All News